Using the eye as a window to the central nervous system for improved drug testing. The annual cost of treating brain illnesses is US$250 billion. Each new drug costs about US$900 million to develop. This research will give Pfizer Pty Ltd, the project’s industry partner, a more efficient and direct way of testing whether drugs can get into and affect the brain. This will reduce the cost of drug development, which ultimately means cheaper drugs. The project will develop new technologies to put Aus ....Using the eye as a window to the central nervous system for improved drug testing. The annual cost of treating brain illnesses is US$250 billion. Each new drug costs about US$900 million to develop. This research will give Pfizer Pty Ltd, the project’s industry partner, a more efficient and direct way of testing whether drugs can get into and affect the brain. This will reduce the cost of drug development, which ultimately means cheaper drugs. The project will develop new technologies to put Australia at the forefront of neuropharmaceutical and neuroscience research. A new research platform will foster collaborations with the pharmaceutical industry both within Australia and overseas. This industrial link will promote a unique post-graduate experience by providing exposure to academic and industrial environments for Australian scientists.Read moreRead less
Rapid detection of rare-event cells by strong UP-conversion
encoded nano-radiators (SUPER Dots): finding a needle in a haystack. Current diagnostic tests are not sensitive enough to detect cancer in its very early stages or early recurrence following treatment. The new technologies developed by this project will be able to find single cancer cells in blood and urine samples heralding a new era in medical diagnostics.
The development of tuneable materials to allow the three-dimensional printing of cells. New low cost three-dimensional (3D) printers and reagents will be developed during this project to allow cancer biologists to print cells and polymers as more realistic 3D tissue models for biological assays. Such technology will be important for performing basic research into cancers as well as for providing better tools for drug testing.
Bioinks for the 3D printing of cells made from off-the-shelf components. This project aims to develop a simple method for creating complex, multiple-cell-type three-dimensional (3D) cell cultures for in-vitro cell based assays. Using 3D printing technology, this project will develop a versatile polymer system, made from entirely commercially available components, that gels upon printing and has functionality to assist cells in adhering, growing and migrating. The 3D printing of multiple cell typ ....Bioinks for the 3D printing of cells made from off-the-shelf components. This project aims to develop a simple method for creating complex, multiple-cell-type three-dimensional (3D) cell cultures for in-vitro cell based assays. Using 3D printing technology, this project will develop a versatile polymer system, made from entirely commercially available components, that gels upon printing and has functionality to assist cells in adhering, growing and migrating. The 3D printing of multiple cell types will provide biological scientists with more realistic in-vitro cell assays to those found in-vivo. Applications of the research are in cell biology, studying diseases and developing new drugs.Read moreRead less
Integrative brain imaging technologies. This project aims to develop quantitative metabolic imaging using simultaneous magnetic resonance imaging (MRI) and positron emission tomography (PET). The current generation of MR-PET scanners are capable of simultaneously acquiring MRI and PET data to enable quantitative anatomical, physiological and metabolic imaging. The project aims to develop new MRI methods for quantitative anatomical mapping, MR-based motion correction of dynamic PET scan data, and ....Integrative brain imaging technologies. This project aims to develop quantitative metabolic imaging using simultaneous magnetic resonance imaging (MRI) and positron emission tomography (PET). The current generation of MR-PET scanners are capable of simultaneously acquiring MRI and PET data to enable quantitative anatomical, physiological and metabolic imaging. The project aims to develop new MRI methods for quantitative anatomical mapping, MR-based motion correction of dynamic PET scan data, and joint estimation of physiological and metabolic organ activity. These advances will create innovative imaging technologies for advanced biomedical imaging research with a particular emphasis in healthy ageing.
Read moreRead less
Proteomic study of urine to discover novel biomarkers for human prostate cancer. The purpose of this project is to identify novel markers in the urine of patients with prostate cancer. These biomarkers may ultimately prove useful in the development of novel diagnostic tools for the management of this disease.
Proteomic study of tears to discover novel biomarkers for human breast cancer. The purpose of this project is to identify novel markers in the tears of patients with breast cancer. The results from this study may improve the prognosis of breast cancer patients.
Imaging Mass Spectrometry (IMS), a peptide biomarker discovery tool using tissue. Cancer is the second most common cause of death in Australia. The newly developed technology of Imaging Mass Spectrometry for peptides in tissue has the potential to discover biomarkers for early diagnosis of cancer. This new technology could avoid a number of cancer deaths and reduce suffering of patients through earlier and better diagnosis.